Related Experiment Video

Updated: Sep 9, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

631

Long Non-Coding RNA VPS9D1-AS1 in Human Cancer: Functions, Mechanisms, and Clinical Utility

Jingjie Yang1,2, Haodong He1,2, Haoran Liu1,2

  • 1Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang 443002, China.

Anti-Cancer Agents in Medicinal Chemistry
|September 5, 2025
PubMed
Abstract

Insights

VPS9D1-AS1, a novel long non-coding RNA, is highly expressed in many cancers and linked to poor prognosis. It acts as a signal, scaffold, guide, and decoy to drive tumor progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • VPS9D1-AS1, also known as MYU or FAISL, is a long non-coding RNA (lncRNA) located on human chromosome 16q24.3.
  • This lncRNA is frequently overexpressed in various human cancers.
  • High VPS9D1-AS1 expression correlates with adverse clinicopathological features and poor prognosis in multiple malignancies.

Purpose of the Study:

  • To investigate the molecular mechanisms and oncogenic roles of VPS9D1-AS1 in cancer.
  • To summarize the current understanding of VPS9D1-AS1's functions in tumor development and progression.

Main Methods:

  • A comprehensive literature search was performed across PubMed, Web of Science, and Google Scholar.
  • Included studies were peer-reviewed publications focusing on VPS9D1-AS1 (MYU, FAISL) in oncology.

Main Results:

  • VPS9D1-AS1 functions mechanistically as a signal, scaffold, guide, and decoy.
  • These roles enable VPS9D1-AS1 to regulate target gene expression and signaling pathways.
  • Its functions contribute to the malignant phenotype of tumors, including proliferation, invasion, and metastasis.

Conclusions:

  • VPS9D1-AS1 is a significant regulator in the development and progression of diverse cancers.
  • Its multifaceted molecular mechanisms underscore its importance in tumor biology.
  • Further research into VPS9D1-AS1 could lead to novel cancer diagnostic and therapeutic strategies.
Keywords:
CancerFAISLMYUVPS9D1-AS1biomarkerlncRNAtherapeutic target

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K
An Enrichment Method for Small Extracellular Vesicles Derived from Liver Cancer Tissue10:33

An Enrichment Method for Small Extracellular Vesicles Derived from Liver Cancer Tissue

Published on: February 3, 2023

1.4K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.1K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.8K